Please ensure Javascript is enabled for purposes of website accessibility
Search
Accessibility Menu

Investing in Gene-Editing Stocks

By Keith Speights – Updated Mar 20, 2025 at 1:55PM

Key Points

  • CRISPR gene-editing technology offers curative potential for genetic diseases.
  • The gene-editing market is projected to reach $30.8 billion by 2032.
  • Top gene-editing pioneers include Intellia Therapeutics, CRISPR Therapeutics, and Beam Therapeutics.
Key findings are powered by ChatGPT and based solely off the content from this article. Findings are reviewed by our editorial team. The author and editors take ultimate responsibility for the content.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.